Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134385 | 0.91 | ADRB2 (0.59) | ADRB2ADRB1CHRM3ADRB3 | |
| SCHEMBL4134389 | 0.91 | ADRB2 (0.59) | ADRB2ADRB1CHRM3ADRB3 | |
| SCHEMBL4139428 | 0.87 | ADRB2 (0.44) | ADRB2ADRB1CHRM3ADRB3 | |
| SCHEMBL4129516 | 0.86 | ADRB2 (0.66) | ADRB2ADRB1DRD2DRD3 | |
| SCHEMBL4134765 | 0.86 | ADRB2 (0.66) | ADRB2ADRB1DRD2DRD3 | |
| SCHEMBL14420472 | 0.85 | ADRB2 (0.58) | ADRB2ADRB1CHRM3DRD2DRD1 | |
| SCHEMBL4139889 | 0.85 | ADRB2 (0.58) | ADRB2ADRB1CHRM3DRD2DRD1 | |
| SCHEMBL4132536 | 0.83 | ADRB2 (0.58) | ADRB2ADRB1CHRM3ADRB3DRD3 | |
| SCHEMBL4129279 | 0.81 | ADRB2 (0.57) | ADRB2ADRB1CHRM3ADRB3DRD2 | |
| SCHEMBL4139870 | 0.81 | ADRB2 (0.57) | ADRB2ADRB1CHRM3DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885CHRM3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.